Worth reading
65In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
81
妊娠阻止率（%）Wording
Conditional
How definitive the wording is.Announced details
ノルレボ®スイッチOTC医薬品（要指導医薬品）
Applicable field (uses covered by this announcement)
緊急避妊、セルフケア、OTC医薬品
Launch date発売時期は未定（発売に向けて準備中）
What the company reported numerically
Quantitative Effects
妊娠阻止率81%。性交から72時間以内に1回服用。
Relationship between the counterparty and the company
ASKA Pharmaceutical Holdings Co.,Ltd.4886
Relationship with the Company
あすか製薬株式会社と共同で本製品を販売。第一三共ヘルスケアが販売元となる。あすか製薬は当社の子会社。
CounterpartyDaiichi Sankyo Healthcare Co., Ltd.
本社：東京都中央区、社長：内田高広。第一三共グループの企業で、OTC医薬品、機能性スキンケア、オーラルケア、食品事業を展開。
Impact on Business Performance
2026年3月期通期業績への影響は現在精査中。影響が生じる場合は速やかに公表予定。
The company does not address Contract Value / Offering price.
Source (materials cited by the company)
世界保健機関（WHO）、令和7年度第2回薬事審議会要指導・一般用医薬品部会
| Item | Details |
|---|---|
| Names of Products / Services Covered | ノルレボ®スイッチOTC医薬品（要指導医薬品） |
| Counterparty | Daiichi Sankyo Healthcare Co., Ltd. |
| Counterparty overview | 本社：東京都中央区、社長：内田高広。第一三共グループの企業で、OTC医薬品、機能性スキンケア、オーラルケア、食品事業を展開。 |
| Relationship with the Company | あすか製薬株式会社と共同で本製品を販売。第一三共ヘルスケアが販売元となる。あすか製薬は当社の子会社。 |
| Launch date | 発売時期は未定（発売に向けて準備中） |
| Applicable area | 緊急避妊、セルフケア、OTC医薬品 |
| Quantitative Effects | 妊娠阻止率81%。性交から72時間以内に1回服用。 |
| Impact on Business Performance | 2026年3月期通期業績への影響は現在精査中。影響が生じる場合は速やかに公表予定。 |
| Source | 世界保健機関（WHO）、令和7年度第2回薬事審議会要指導・一般用医薬品部会 |
Items this document does not state (9)
Contract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleUsage history
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.様々な要望に対応できる体制を整えるため、製造販売承認申請を行った。第一三共ヘルスケアは、より安全に使用できるよう適正販売・適正使用を推進する。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.